| 1 |
Hiramine Y, Uto H, Mawatari S, Kanmura S, Imamura Y, Hiwaki T, Saishoji A, Kakihara A, Maenohara S, Tokushige K, Ido A. Efficacy of rifaximin, a poorly absorbed rifamycin antimicrobial agent, for hepatic encephalopathy in Japanese patients. Hepatol Res 2021;51:445-60. [PMID: 33533150 DOI: 10.1111/hepr.13622] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 2 |
Bai Z, Cheng G, Méndez-Sánchez N, Qi X. Human albumin infusion strategy in liver cirrhosis: liberal or restrictive? Ann Transl Med 2021;9:1114. [PMID: 34430555 DOI: 10.21037/atm-21-2136] [Reference Citation Analysis]
|
| 3 |
Henkel S, Vetterly C, Squires R, McKiernan P, Squires J. Pharmacological management of portal hypertension and its complications in children: lessons from adults and opportunities for the future. Expert Opin Pharmacother 2021;22:291-304. [PMID: 33074032 DOI: 10.1080/14656566.2020.1825685] [Reference Citation Analysis]
|
| 4 |
Castro-Narro G, Moctezuma-Velázquez C, Male-Velázquez R, Trejo-Estrada R, Bosques FJ, Moreno-Alcántar R, Rodríguez-Hernández H, Bautista-Santos A, Córtez-Hernández C, Cerda-Reyes E, Pérez-Escobar J, Aldana-Ledesma JM, Aguirre-Valadez J, Ruiz-Velasco JAV, Contreras-Omaña R, Miranda-Zazueta G, Reyes-Bastidas MDR, Meza-Cardona JM, Chávez-Tapia N, Fernández-Pérez NJ, García-Jiménez ES, Torre A. POSITION STATEMENT ON THE USE OF ALBUMIN IN LIVER CIRRHOSIS. Ann Hepatol 2022;:100708. [PMID: 35550187 DOI: 10.1016/j.aohep.2022.100708] [Reference Citation Analysis]
|
| 5 |
Ridola L, Faccioli J, Nardelli S, Gioia S, Riggio O. Hepatic Encephalopathy: Diagnosis and Management. J Transl Int Med 2020;8:210-9. [PMID: 33511048 DOI: 10.2478/jtim-2020-0034] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 6 |
Li J, Feng D, Pang N, Zhao C, Gao L, Liu S, Li L. Controlling nutritional status score as a new indicator of overt hepatic encephalopathy in cirrhotic patients following transjugular intrahepatic portosystemic shunt. Clinical Nutrition 2022;41:560-6. [DOI: 10.1016/j.clnu.2021.12.036] [Reference Citation Analysis]
|
| 7 |
Teh KB, Loo JH, Tam YC, Wong YJ. Efficacy and safety of albumin infusion for overt hepatic encephalopathy: A systematic review and meta-analysis. Dig Liver Dis 2021;53:817-23. [PMID: 34011479 DOI: 10.1016/j.dld.2021.04.030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 8 |
Hasan LZ, Wu GY. Novel Agents in the Management of Hepatic Encephalopathy: A Review. J Clin Transl Hepatol 2021;9:749-59. [PMID: 34722190 DOI: 10.14218/JCTH.2021.00102] [Reference Citation Analysis]
|
| 9 |
Duah A, Agyei-Nkansah A, Osei-Poku F, Duah F, Ampofo-Boobi D, Peprah B. The Prevalence, Predictors, and In-Hospital Mortality of Hepatic Encephalopathy in Patients with Liver Cirrhosis Admitted at St. Dominic Hospital in Akwatia, Ghana. Can J Gastroenterol Hepatol 2020;2020:8816522. [PMID: 33425806 DOI: 10.1155/2020/8816522] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 10 |
Tufoni M, Zaccherini G, Caraceni P, Bernardi M. Albumin: Indications in chronic liver disease. United European Gastroenterol J 2020;8:528-35. [PMID: 32213034 DOI: 10.1177/2050640620910339] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 11 |
Is B, Bombassaro IZ, Tovo CV, de Mattos ÂZ, Ahlert M, Chiesa T, de Mattos AA. Albumin in the management of hepatic encephalopathy: A systematic review and meta-analysis. Ann Hepatol 2021;26:100541. [PMID: 34600143 DOI: 10.1016/j.aohep.2021.100541] [Reference Citation Analysis]
|
| 12 |
Mangini C, Montagnese S. New Therapies of Liver Diseases: Hepatic Encephalopathy. J Clin Med 2021;10:4050. [PMID: 34575157 DOI: 10.3390/jcm10184050] [Reference Citation Analysis]
|
